Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

GSK plc to seek dismissal of upcoming Wilson case in Florida

GSK welcomes the Florida State Court's Daubert ruling excluding unreliable expert testimony, seeking dismissal of the Wilson case alleging ranitidine-prostate cancer link...

GSK wins jury verdict in Illinois ranitidine cancer case

GSK plc welcome favorable jury verdict in Illinois, ruling out any liability for plaintiff's colorectal cancer linked to ranitidine use...

AstraZeneca Plc completes acquisition of Amolyt Pharma

AstraZeneca plc (LON: AZN) has completed the acquisition of Amolyt Pharma, enhancing its rare disease pipeline and expanding its bone metabolism franchise...

Aptamer Group signs agreement with AstraZeneca to explore Optimer delivery vehicles

Aptamer Group plc has partnered with AstraZeneca to evaluate Optimer® binders for targeted siRNA delivery to fibrotic liver cells, aiming to innovate gene therapies...

GSK and CureVac to restructure collaboration into new licensing agreement

GSK plc and CureVac N.V. restructure their collaboration into a licensing agreement, enhancing mRNA vaccine development for influenza and COVID-19...

GSK’s Omjjara approved in Japan for treatment of myelofibrosis

GSK's Omjjara (momelotinib) gains approval from Japan's MHLW for treating myelofibrosis, addressing anaemia, symptoms, and splenomegaly in patients...

AstraZeneca’s Imfinzi plus chemotherapy approved in the US for endometrial cancer

AstraZeneca's Imfinzi gains FDA approval for endometrial cancer treatment. Results show significant benefits for patients with dMMR disease...

Hikma enhances Injectables pipeline and manufacturing capabilities with Xellia acquisition

Hikma Pharmaceuticals PLC announces agreement to acquire parts of Xellia Pharmaceuticals' US business, expanding its injectables portfolio and manufacturing capabilities...

GSK starts appeal process of recent Delaware Daubert decision

GSK seeks appeal of recent Daubert ruling in Zantac litigation in Delaware Superior Court. Scientific consensus disputes claim of increased cancer risk...

GSK’s Arexvy RSV vaccine approved for adults 50-59 at risk of LRTD

GSK secures FDA approval for Arexvy in adults aged 50-59 at increased risk for RSV-LRTD. Clinical development ongoing, expanding vaccine benefits globally...

AstraZeneca completes acquisition of Fusion Pharmaceuticals

AstraZeneca completes acquisition of Fusion Pharmaceuticals, enhancing its oncology portfolio with next-gen radioconjugates. Learn more here...

AstraZeneca Plc Tagrisso recommended for approval in the EU for NSCLC treatment

AstraZeneca's Tagrisso recommended EU approval for 1st-line treatment of EGFRm NSCLC with positive results from FLAURA2 trial published in NEJM...

GSK Plc Second trial to show robust efficacy for a Blenrep combination

GSK plc announces positive results from DREAMM-8 trial at ASCO 2024, showing significant improvements in PFS for Blenrep combination therapy...

GSK Plc wins jury verdict in Zantac case and dismissal of next trial

GSK plc celebrates favorable jury verdict in first Zantac trial, highlighting scientific consensus on ranitidine safety and ongoing defense against claims...
Search

Funds

Health

GSK plc to seek dismissal of upcoming Wilson case in Florida

GSK welcomes the Florida State Court's Daubert ruling excluding unreliable expert testimony, seeking dismissal of the Wilson case alleging ranitidine-prostate cancer link...

GSK wins jury verdict in Illinois ranitidine cancer case

GSK plc welcome favorable jury verdict in Illinois, ruling out any liability for plaintiff's colorectal cancer linked to ranitidine use...

AstraZeneca Plc completes acquisition of Amolyt Pharma

AstraZeneca plc (LON: AZN) has completed the acquisition of Amolyt Pharma, enhancing its rare disease pipeline and expanding its bone metabolism franchise...

Aptamer Group signs agreement with AstraZeneca to explore Optimer delivery vehicles

Aptamer Group plc has partnered with AstraZeneca to evaluate Optimer® binders for targeted siRNA delivery to fibrotic liver cells, aiming to innovate gene therapies...

GSK and CureVac to restructure collaboration into new licensing agreement

GSK plc and CureVac N.V. restructure their collaboration into a licensing agreement, enhancing mRNA vaccine development for influenza and COVID-19...

GSK’s Omjjara approved in Japan for treatment of myelofibrosis

GSK's Omjjara (momelotinib) gains approval from Japan's MHLW for treating myelofibrosis, addressing anaemia, symptoms, and splenomegaly in patients...

AstraZeneca’s Imfinzi plus chemotherapy approved in the US for endometrial cancer

AstraZeneca's Imfinzi gains FDA approval for endometrial cancer treatment. Results show significant benefits for patients with dMMR disease...

Hikma enhances Injectables pipeline and manufacturing capabilities with Xellia acquisition

Hikma Pharmaceuticals PLC announces agreement to acquire parts of Xellia Pharmaceuticals' US business, expanding its injectables portfolio and manufacturing capabilities...

GSK starts appeal process of recent Delaware Daubert decision

GSK seeks appeal of recent Daubert ruling in Zantac litigation in Delaware Superior Court. Scientific consensus disputes claim of increased cancer risk...

GSK’s Arexvy RSV vaccine approved for adults 50-59 at risk of LRTD

GSK secures FDA approval for Arexvy in adults aged 50-59 at increased risk for RSV-LRTD. Clinical development ongoing, expanding vaccine benefits globally...

AstraZeneca completes acquisition of Fusion Pharmaceuticals

AstraZeneca completes acquisition of Fusion Pharmaceuticals, enhancing its oncology portfolio with next-gen radioconjugates. Learn more here...

AstraZeneca Plc Tagrisso recommended for approval in the EU for NSCLC treatment

AstraZeneca's Tagrisso recommended EU approval for 1st-line treatment of EGFRm NSCLC with positive results from FLAURA2 trial published in NEJM...

GSK Plc Second trial to show robust efficacy for a Blenrep combination

GSK plc announces positive results from DREAMM-8 trial at ASCO 2024, showing significant improvements in PFS for Blenrep combination therapy...

GSK Plc wins jury verdict in Zantac case and dismissal of next trial

GSK plc celebrates favorable jury verdict in first Zantac trial, highlighting scientific consensus on ranitidine safety and ongoing defense against claims...
Search

Funds

Health

FTSE 100

Funds